nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—EGFR—chronic obstructive pulmonary disease	0.206	0.409	CbGaD
Erlotinib—CYP1A1—chronic obstructive pulmonary disease	0.118	0.234	CbGaD
Erlotinib—CYP1A2—chronic obstructive pulmonary disease	0.114	0.226	CbGaD
Erlotinib—SLCO2B1—Montelukast—chronic obstructive pulmonary disease	0.0953	0.355	CbGbCtD
Erlotinib—ALB—chronic obstructive pulmonary disease	0.0657	0.13	CbGaD
Erlotinib—CYP2C8—Montelukast—chronic obstructive pulmonary disease	0.0208	0.0777	CbGbCtD
Erlotinib—CYP1A2—Aminophylline—chronic obstructive pulmonary disease	0.0181	0.0675	CbGbCtD
Erlotinib—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.0175	0.0654	CbGbCtD
Erlotinib—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.0175	0.0654	CbGbCtD
Erlotinib—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0156	0.0583	CbGbCtD
Erlotinib—ALB—Prednisone—chronic obstructive pulmonary disease	0.0149	0.0557	CbGbCtD
Erlotinib—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0147	0.0549	CbGbCtD
Erlotinib—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.00994	0.0371	CbGbCtD
Erlotinib—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.00949	0.0354	CbGbCtD
Erlotinib—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.00845	0.0315	CbGbCtD
Erlotinib—ABCB1—Prednisolone—chronic obstructive pulmonary disease	0.00828	0.0309	CbGbCtD
Erlotinib—ABCB1—Prednisone—chronic obstructive pulmonary disease	0.00782	0.0291	CbGbCtD
Erlotinib—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.00496	0.0185	CbGbCtD
Erlotinib—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.00469	0.0175	CbGbCtD
Erlotinib—MAP3K19—respiratory system—chronic obstructive pulmonary disease	0.00182	0.0442	CbGeAlD
Erlotinib—JAK3—connective tissue—chronic obstructive pulmonary disease	0.00176	0.0428	CbGeAlD
Erlotinib—FLT3—respiratory system—chronic obstructive pulmonary disease	0.00158	0.0384	CbGeAlD
Erlotinib—TNK1—bronchus—chronic obstructive pulmonary disease	0.00151	0.0367	CbGeAlD
Erlotinib—FLT3—connective tissue—chronic obstructive pulmonary disease	0.00139	0.0338	CbGeAlD
Erlotinib—TNK1—trachea—chronic obstructive pulmonary disease	0.00136	0.033	CbGeAlD
Erlotinib—Vandetanib—ERBB3—chronic obstructive pulmonary disease	0.00133	0.258	CrCbGaD
Erlotinib—LTK—lung—chronic obstructive pulmonary disease	0.00133	0.0323	CbGeAlD
Erlotinib—Gefitinib—ERBB3—chronic obstructive pulmonary disease	0.00126	0.245	CrCbGaD
Erlotinib—PIP4K2C—bronchus—chronic obstructive pulmonary disease	0.00117	0.0285	CbGeAlD
Erlotinib—ULK3—bronchus—chronic obstructive pulmonary disease	0.00112	0.0272	CbGeAlD
Erlotinib—JAK3—lung—chronic obstructive pulmonary disease	0.00106	0.0258	CbGeAlD
Erlotinib—STK10—respiratory system—chronic obstructive pulmonary disease	0.00105	0.0256	CbGeAlD
Erlotinib—MKNK1—bronchus—chronic obstructive pulmonary disease	0.00105	0.0256	CbGeAlD
Erlotinib—PIP4K2C—trachea—chronic obstructive pulmonary disease	0.00105	0.0256	CbGeAlD
Erlotinib—ULK3—trachea—chronic obstructive pulmonary disease	0.001	0.0245	CbGeAlD
Erlotinib—SLK—bronchus—chronic obstructive pulmonary disease	0.000997	0.0243	CbGeAlD
Erlotinib—TNK1—lung—chronic obstructive pulmonary disease	0.000974	0.0237	CbGeAlD
Erlotinib—MAP3K19—lung—chronic obstructive pulmonary disease	0.000964	0.0235	CbGeAlD
Erlotinib—SLK—trachea—chronic obstructive pulmonary disease	0.000895	0.0218	CbGeAlD
Erlotinib—STK10—bronchus—chronic obstructive pulmonary disease	0.000867	0.0211	CbGeAlD
Erlotinib—FLT3—lung—chronic obstructive pulmonary disease	0.000837	0.0204	CbGeAlD
Erlotinib—ABL2—lung—chronic obstructive pulmonary disease	0.000799	0.0194	CbGeAlD
Erlotinib—EGFR—lung—chronic obstructive pulmonary disease	0.00078	0.019	CbGeAlD
Erlotinib—MAP2K5—bronchus—chronic obstructive pulmonary disease	0.000774	0.0188	CbGeAlD
Erlotinib—PIP4K2C—lung—chronic obstructive pulmonary disease	0.000756	0.0184	CbGeAlD
Erlotinib—SLCO2B1—respiratory system—chronic obstructive pulmonary disease	0.000732	0.0178	CbGeAlD
Erlotinib—ABL1—respiratory system—chronic obstructive pulmonary disease	0.000726	0.0177	CbGeAlD
Erlotinib—ULK3—lung—chronic obstructive pulmonary disease	0.000722	0.0176	CbGeAlD
Erlotinib—Vandetanib—VEGFA—chronic obstructive pulmonary disease	0.000706	0.137	CrCbGaD
Erlotinib—MAP2K5—trachea—chronic obstructive pulmonary disease	0.000695	0.0169	CbGeAlD
Erlotinib—MKNK1—lung—chronic obstructive pulmonary disease	0.000679	0.0165	CbGeAlD
Erlotinib—SLK—lung—chronic obstructive pulmonary disease	0.000643	0.0157	CbGeAlD
Erlotinib—ABL1—connective tissue—chronic obstructive pulmonary disease	0.000639	0.0156	CbGeAlD
Erlotinib—CYP1B1—respiratory system—chronic obstructive pulmonary disease	0.000615	0.015	CbGeAlD
Erlotinib—ABL1—bronchus—chronic obstructive pulmonary disease	0.000597	0.0145	CbGeAlD
Erlotinib—Vandetanib—EGFR—chronic obstructive pulmonary disease	0.000595	0.116	CrCbGaD
Erlotinib—ABL1—smooth muscle tissue—chronic obstructive pulmonary disease	0.000584	0.0142	CbGeAlD
Erlotinib—Gefitinib—EGFR—chronic obstructive pulmonary disease	0.000566	0.11	CrCbGaD
Erlotinib—STK10—lung—chronic obstructive pulmonary disease	0.000559	0.0136	CbGeAlD
Erlotinib—CYP1B1—connective tissue—chronic obstructive pulmonary disease	0.000541	0.0132	CbGeAlD
Erlotinib—ABL1—trachea—chronic obstructive pulmonary disease	0.000536	0.0131	CbGeAlD
Erlotinib—MAP2K5—lung—chronic obstructive pulmonary disease	0.000499	0.0122	CbGeAlD
Erlotinib—CYP1B1—smooth muscle tissue—chronic obstructive pulmonary disease	0.000495	0.012	CbGeAlD
Erlotinib—CYP1A2—respiratory system—chronic obstructive pulmonary disease	0.00044	0.0107	CbGeAlD
Erlotinib—CYP1A1—respiratory system—chronic obstructive pulmonary disease	0.000434	0.0106	CbGeAlD
Erlotinib—CYP3A5—respiratory system—chronic obstructive pulmonary disease	0.000425	0.0103	CbGeAlD
Erlotinib—ORM1—lung—chronic obstructive pulmonary disease	0.000406	0.00987	CbGeAlD
Erlotinib—SLCO2B1—lung—chronic obstructive pulmonary disease	0.000389	0.00946	CbGeAlD
Erlotinib—ABL1—lung—chronic obstructive pulmonary disease	0.000385	0.00938	CbGeAlD
Erlotinib—CYP1A1—bronchus—chronic obstructive pulmonary disease	0.000358	0.0087	CbGeAlD
Erlotinib—CYP1B1—lung—chronic obstructive pulmonary disease	0.000326	0.00794	CbGeAlD
Erlotinib—Gefitinib—CYP1A1—chronic obstructive pulmonary disease	0.000324	0.0629	CrCbGaD
Erlotinib—CYP1A1—trachea—chronic obstructive pulmonary disease	0.000321	0.00782	CbGeAlD
Erlotinib—Anorexia—Aminophylline—chronic obstructive pulmonary disease	0.000261	0.00242	CcSEcCtD
Erlotinib—Mediastinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000259	0.0024	CcSEcCtD
Erlotinib—Rash—Roflumilast—chronic obstructive pulmonary disease	0.000259	0.0024	CcSEcCtD
Erlotinib—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.000259	0.0024	CcSEcCtD
Erlotinib—Oedema—Tiotropium—chronic obstructive pulmonary disease	0.000258	0.0024	CcSEcCtD
Erlotinib—Headache—Roflumilast—chronic obstructive pulmonary disease	0.000257	0.00239	CcSEcCtD
Erlotinib—Mental disorder—Formoterol—chronic obstructive pulmonary disease	0.000257	0.00239	CcSEcCtD
Erlotinib—Mental disorder—Arformoterol—chronic obstructive pulmonary disease	0.000257	0.00239	CcSEcCtD
Erlotinib—Infection—Tiotropium—chronic obstructive pulmonary disease	0.000256	0.00238	CcSEcCtD
Erlotinib—Malnutrition—Formoterol—chronic obstructive pulmonary disease	0.000255	0.00237	CcSEcCtD
Erlotinib—Malnutrition—Arformoterol—chronic obstructive pulmonary disease	0.000255	0.00237	CcSEcCtD
Erlotinib—Shock—Tiotropium—chronic obstructive pulmonary disease	0.000254	0.00236	CcSEcCtD
Erlotinib—Nervous system disorder—Tiotropium—chronic obstructive pulmonary disease	0.000253	0.00235	CcSEcCtD
Erlotinib—Mental disorder—Montelukast—chronic obstructive pulmonary disease	0.000252	0.00234	CcSEcCtD
Erlotinib—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.000251	0.00233	CcSEcCtD
Erlotinib—Mediastinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.00025	0.00232	CcSEcCtD
Erlotinib—Chills—Salbutamol—chronic obstructive pulmonary disease	0.000248	0.00231	CcSEcCtD
Erlotinib—Insomnia—Aminophylline—chronic obstructive pulmonary disease	0.000248	0.0023	CcSEcCtD
Erlotinib—Arrhythmia—Salbutamol—chronic obstructive pulmonary disease	0.000247	0.0023	CcSEcCtD
Erlotinib—Back pain—Formoterol—chronic obstructive pulmonary disease	0.000247	0.00229	CcSEcCtD
Erlotinib—Back pain—Arformoterol—chronic obstructive pulmonary disease	0.000247	0.00229	CcSEcCtD
Erlotinib—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.000244	0.00226	CcSEcCtD
Erlotinib—ABCG2—lung—chronic obstructive pulmonary disease	0.000243	0.00592	CbGeAlD
Erlotinib—Mental disorder—Salbutamol—chronic obstructive pulmonary disease	0.000243	0.00225	CcSEcCtD
Erlotinib—Malnutrition—Salbutamol—chronic obstructive pulmonary disease	0.000241	0.00224	CcSEcCtD
Erlotinib—Dyspepsia—Aminophylline—chronic obstructive pulmonary disease	0.000241	0.00224	CcSEcCtD
Erlotinib—Dermatitis bullous—Prednisolone—chronic obstructive pulmonary disease	0.00024	0.00223	CcSEcCtD
Erlotinib—Decreased appetite—Aminophylline—chronic obstructive pulmonary disease	0.000238	0.00221	CcSEcCtD
Erlotinib—Flatulence—Salbutamol—chronic obstructive pulmonary disease	0.000237	0.00221	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Tiotropium—chronic obstructive pulmonary disease	0.000235	0.00218	CcSEcCtD
Erlotinib—CYP1A2—lung—chronic obstructive pulmonary disease	0.000234	0.00569	CbGeAlD
Erlotinib—Insomnia—Tiotropium—chronic obstructive pulmonary disease	0.000233	0.00217	CcSEcCtD
Erlotinib—Back pain—Salbutamol—chronic obstructive pulmonary disease	0.000233	0.00216	CcSEcCtD
Erlotinib—CYP1A1—lung—chronic obstructive pulmonary disease	0.000231	0.00562	CbGeAlD
Erlotinib—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.000227	0.00211	CcSEcCtD
Erlotinib—ABCB1—respiratory system—chronic obstructive pulmonary disease	0.000226	0.00549	CbGeAlD
Erlotinib—CYP3A5—lung—chronic obstructive pulmonary disease	0.000226	0.00549	CbGeAlD
Erlotinib—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.000224	0.00208	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000223	0.00207	CcSEcCtD
Erlotinib—Cough—Formoterol—chronic obstructive pulmonary disease	0.000223	0.00207	CcSEcCtD
Erlotinib—Cough—Arformoterol—chronic obstructive pulmonary disease	0.000223	0.00207	CcSEcCtD
Erlotinib—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000221	0.00205	CcSEcCtD
Erlotinib—Skin exfoliation—Prednisone—chronic obstructive pulmonary disease	0.000219	0.00204	CcSEcCtD
Erlotinib—Cough—Montelukast—chronic obstructive pulmonary disease	0.000218	0.00203	CcSEcCtD
Erlotinib—Chest pain—Arformoterol—chronic obstructive pulmonary disease	0.000217	0.00202	CcSEcCtD
Erlotinib—Myalgia—Arformoterol—chronic obstructive pulmonary disease	0.000217	0.00202	CcSEcCtD
Erlotinib—Chest pain—Formoterol—chronic obstructive pulmonary disease	0.000217	0.00202	CcSEcCtD
Erlotinib—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	0.000217	0.00202	CcSEcCtD
Erlotinib—Arthralgia—Formoterol—chronic obstructive pulmonary disease	0.000217	0.00202	CcSEcCtD
Erlotinib—Myalgia—Formoterol—chronic obstructive pulmonary disease	0.000217	0.00202	CcSEcCtD
Erlotinib—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.000217	0.00201	CcSEcCtD
Erlotinib—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.000217	0.00201	CcSEcCtD
Erlotinib—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000216	0.00201	CcSEcCtD
Erlotinib—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000216	0.00201	CcSEcCtD
Erlotinib—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.000216	0.00201	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.000216	0.002	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.000216	0.002	CcSEcCtD
Erlotinib—Neuropathy—Prednisone—chronic obstructive pulmonary disease	0.000216	0.002	CcSEcCtD
Erlotinib—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.000213	0.00198	CcSEcCtD
Erlotinib—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.000213	0.00198	CcSEcCtD
Erlotinib—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.000212	0.00197	CcSEcCtD
Erlotinib—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.000212	0.00197	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000211	0.00196	CcSEcCtD
Erlotinib—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000211	0.00196	CcSEcCtD
Erlotinib—Dry skin—Prednisolone—chronic obstructive pulmonary disease	0.00021	0.00195	CcSEcCtD
Erlotinib—Cough—Salbutamol—chronic obstructive pulmonary disease	0.00021	0.00195	CcSEcCtD
Erlotinib—Oedema—Formoterol—chronic obstructive pulmonary disease	0.000208	0.00193	CcSEcCtD
Erlotinib—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.000208	0.00193	CcSEcCtD
Erlotinib—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000207	0.00192	CcSEcCtD
Erlotinib—Infection—Formoterol—chronic obstructive pulmonary disease	0.000207	0.00192	CcSEcCtD
Erlotinib—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000205	0.00191	CcSEcCtD
Erlotinib—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.000205	0.00191	CcSEcCtD
Erlotinib—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000205	0.00191	CcSEcCtD
Erlotinib—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000204	0.0019	CcSEcCtD
Erlotinib—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000204	0.0019	CcSEcCtD
Erlotinib—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000204	0.0019	CcSEcCtD
Erlotinib—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000204	0.00189	CcSEcCtD
Erlotinib—Oedema—Montelukast—chronic obstructive pulmonary disease	0.000204	0.00189	CcSEcCtD
Erlotinib—Infection—Montelukast—chronic obstructive pulmonary disease	0.000203	0.00188	CcSEcCtD
Erlotinib—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000202	0.00188	CcSEcCtD
Erlotinib—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000202	0.00188	CcSEcCtD
Erlotinib—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.0002	0.00186	CcSEcCtD
Erlotinib—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.0002	0.00185	CcSEcCtD
Erlotinib—Sepsis—Prednisone—chronic obstructive pulmonary disease	0.000199	0.00185	CcSEcCtD
Erlotinib—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000198	0.00184	CcSEcCtD
Erlotinib—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000197	0.00183	CcSEcCtD
Erlotinib—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000195	0.00181	CcSEcCtD
Erlotinib—Pancreatitis—Prednisolone—chronic obstructive pulmonary disease	0.000195	0.00181	CcSEcCtD
Erlotinib—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000194	0.0018	CcSEcCtD
Erlotinib—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000194	0.0018	CcSEcCtD
Erlotinib—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000193	0.00179	CcSEcCtD
Erlotinib—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000191	0.00177	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.00019	0.00176	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.00019	0.00176	CcSEcCtD
Erlotinib—Vandetanib—ALB—chronic obstructive pulmonary disease	0.00019	0.0368	CrCbGaD
Erlotinib—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000188	0.00175	CcSEcCtD
Erlotinib—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000188	0.00175	CcSEcCtD
Erlotinib—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000187	0.00174	CcSEcCtD
Erlotinib—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000187	0.00174	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000186	0.00173	CcSEcCtD
Erlotinib—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000186	0.00172	CcSEcCtD
Erlotinib—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000186	0.00172	CcSEcCtD
Erlotinib—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000185	0.00171	CcSEcCtD
Erlotinib—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000183	0.0017	CcSEcCtD
Erlotinib—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000183	0.0017	CcSEcCtD
Erlotinib—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000183	0.0017	CcSEcCtD
Erlotinib—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000181	0.00168	CcSEcCtD
Erlotinib—Gefitinib—ALB—chronic obstructive pulmonary disease	0.00018	0.035	CrCbGaD
Erlotinib—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.00018	0.00167	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.00018	0.00167	CcSEcCtD
Erlotinib—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.00018	0.00167	CcSEcCtD
Erlotinib—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.00018	0.00167	CcSEcCtD
Erlotinib—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.00018	0.00167	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000179	0.00166	CcSEcCtD
Erlotinib—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000178	0.00165	CcSEcCtD
Erlotinib—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000178	0.00165	CcSEcCtD
Erlotinib—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000178	0.00165	CcSEcCtD
Erlotinib—Pain—Formoterol—chronic obstructive pulmonary disease	0.000178	0.00165	CcSEcCtD
Erlotinib—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000178	0.00165	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000176	0.00164	CcSEcCtD
Erlotinib—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000176	0.00163	CcSEcCtD
Erlotinib—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000175	0.00163	CcSEcCtD
Erlotinib—Pain—Montelukast—chronic obstructive pulmonary disease	0.000174	0.00162	CcSEcCtD
Erlotinib—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	0.000174	0.00162	CcSEcCtD
Erlotinib—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000174	0.00162	CcSEcCtD
Erlotinib—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	0.000173	0.00161	CcSEcCtD
Erlotinib—Neuropathy peripheral—Prednisolone—chronic obstructive pulmonary disease	0.000173	0.00161	CcSEcCtD
Erlotinib—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000173	0.00161	CcSEcCtD
Erlotinib—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000173	0.0016	CcSEcCtD
Erlotinib—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000172	0.0016	CcSEcCtD
Erlotinib—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	0.000172	0.0016	CcSEcCtD
Erlotinib—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000171	0.00159	CcSEcCtD
Erlotinib—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000171	0.00159	CcSEcCtD
Erlotinib—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000171	0.00158	CcSEcCtD
Erlotinib—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.00017	0.00158	CcSEcCtD
Erlotinib—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.00017	0.00158	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.00017	0.00158	CcSEcCtD
Erlotinib—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.00017	0.00157	CcSEcCtD
Erlotinib—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000168	0.00156	CcSEcCtD
Erlotinib—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000168	0.00156	CcSEcCtD
Erlotinib—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000167	0.00155	CcSEcCtD
Erlotinib—Gastrointestinal haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000167	0.00155	CcSEcCtD
Erlotinib—ABCB1—trachea—chronic obstructive pulmonary disease	0.000167	0.00406	CbGeAlD
Erlotinib—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000165	0.00153	CcSEcCtD
Erlotinib—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000165	0.00153	CcSEcCtD
Erlotinib—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000165	0.00153	CcSEcCtD
Erlotinib—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000165	0.00153	CcSEcCtD
Erlotinib—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000164	0.00152	CcSEcCtD
Erlotinib—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000163	0.00151	CcSEcCtD
Erlotinib—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000163	0.00151	CcSEcCtD
Erlotinib—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000163	0.00151	CcSEcCtD
Erlotinib—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000162	0.0015	CcSEcCtD
Erlotinib—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000161	0.0015	CcSEcCtD
Erlotinib—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000161	0.0015	CcSEcCtD
Erlotinib—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000161	0.00149	CcSEcCtD
Erlotinib—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	0.00016	0.00148	CcSEcCtD
Erlotinib—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	0.000159	0.00147	CcSEcCtD
Erlotinib—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000155	0.00144	CcSEcCtD
Erlotinib—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000155	0.00144	CcSEcCtD
Erlotinib—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000153	0.00142	CcSEcCtD
Erlotinib—Dry skin—Prednisone—chronic obstructive pulmonary disease	0.000153	0.00142	CcSEcCtD
Erlotinib—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	0.000152	0.00141	CcSEcCtD
Erlotinib—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000149	0.00139	CcSEcCtD
Erlotinib—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000149	0.00139	CcSEcCtD
Erlotinib—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000147	0.00137	CcSEcCtD
Erlotinib—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000147	0.00137	CcSEcCtD
Erlotinib—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.000147	0.00137	CcSEcCtD
Erlotinib—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000146	0.00136	CcSEcCtD
Erlotinib—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000144	0.00134	CcSEcCtD
Erlotinib—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000143	0.00132	CcSEcCtD
Erlotinib—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000143	0.00132	CcSEcCtD
Erlotinib—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.000142	0.00132	CcSEcCtD
Erlotinib—Pancreatitis—Prednisone—chronic obstructive pulmonary disease	0.000141	0.00131	CcSEcCtD
Erlotinib—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000141	0.00131	CcSEcCtD
Erlotinib—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.00014	0.0013	CcSEcCtD
Erlotinib—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000139	0.00129	CcSEcCtD
Erlotinib—Erythema—Prednisolone—chronic obstructive pulmonary disease	0.000138	0.00128	CcSEcCtD
Erlotinib—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000138	0.00128	CcSEcCtD
Erlotinib—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000138	0.00128	CcSEcCtD
Erlotinib—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000135	0.00125	CcSEcCtD
Erlotinib—Neutropenia—Prednisone—chronic obstructive pulmonary disease	0.000135	0.00125	CcSEcCtD
Erlotinib—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000135	0.00125	CcSEcCtD
Erlotinib—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000132	0.00123	CcSEcCtD
Erlotinib—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000132	0.00123	CcSEcCtD
Erlotinib—Rash—Formoterol—chronic obstructive pulmonary disease	0.000131	0.00122	CcSEcCtD
Erlotinib—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000131	0.00122	CcSEcCtD
Erlotinib—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000131	0.00122	CcSEcCtD
Erlotinib—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000131	0.00122	CcSEcCtD
Erlotinib—Headache—Formoterol—chronic obstructive pulmonary disease	0.000131	0.00121	CcSEcCtD
Erlotinib—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000131	0.00121	CcSEcCtD
Erlotinib—Weight decreased—Prednisone—chronic obstructive pulmonary disease	0.00013	0.00121	CcSEcCtD
Erlotinib—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.00013	0.00121	CcSEcCtD
Erlotinib—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.00013	0.0012	CcSEcCtD
Erlotinib—Rash—Montelukast—chronic obstructive pulmonary disease	0.000129	0.00119	CcSEcCtD
Erlotinib—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000129	0.00119	CcSEcCtD
Erlotinib—Depression—Prednisone—chronic obstructive pulmonary disease	0.000128	0.00119	CcSEcCtD
Erlotinib—Headache—Montelukast—chronic obstructive pulmonary disease	0.000128	0.00119	CcSEcCtD
Erlotinib—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	0.000127	0.00118	CcSEcCtD
Erlotinib—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	0.000126	0.00117	CcSEcCtD
Erlotinib—Neuropathy peripheral—Prednisone—chronic obstructive pulmonary disease	0.000126	0.00117	CcSEcCtD
Erlotinib—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000125	0.00116	CcSEcCtD
Erlotinib—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000124	0.00115	CcSEcCtD
Erlotinib—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000124	0.00115	CcSEcCtD
Erlotinib—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000124	0.00115	CcSEcCtD
Erlotinib—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000124	0.00115	CcSEcCtD
Erlotinib—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000124	0.00115	CcSEcCtD
Erlotinib—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000123	0.00114	CcSEcCtD
Erlotinib—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000121	0.00113	CcSEcCtD
Erlotinib—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000121	0.00113	CcSEcCtD
Erlotinib—ABCB1—lung—chronic obstructive pulmonary disease	0.00012	0.00292	CbGeAlD
Erlotinib—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000117	0.00108	CcSEcCtD
Erlotinib—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	0.000116	0.00108	CcSEcCtD
Erlotinib—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000115	0.00107	CcSEcCtD
Erlotinib—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.000113	0.00105	CcSEcCtD
Erlotinib—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000113	0.00105	CcSEcCtD
Erlotinib—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000111	0.00103	CcSEcCtD
Erlotinib—Eye disorder—Prednisone—chronic obstructive pulmonary disease	0.000108	0.001	CcSEcCtD
Erlotinib—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	0.000103	0.000957	CcSEcCtD
Erlotinib—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000102	0.000947	CcSEcCtD
Erlotinib—Alopecia—Prednisone—chronic obstructive pulmonary disease	0.000102	0.000947	CcSEcCtD
Erlotinib—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.000101	0.000939	CcSEcCtD
Erlotinib—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.0001	0.000933	CcSEcCtD
Erlotinib—Erythema—Prednisone—chronic obstructive pulmonary disease	0.0001	0.000933	CcSEcCtD
Erlotinib—Pain—Prednisolone—chronic obstructive pulmonary disease	9.65e-05	0.000896	CcSEcCtD
Erlotinib—Syncope—Prednisone—chronic obstructive pulmonary disease	9.01e-05	0.000836	CcSEcCtD
Erlotinib—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	8.83e-05	0.00082	CcSEcCtD
Erlotinib—Arthralgia—Prednisone—chronic obstructive pulmonary disease	8.55e-05	0.000794	CcSEcCtD
Erlotinib—Myalgia—Prednisone—chronic obstructive pulmonary disease	8.55e-05	0.000794	CcSEcCtD
Erlotinib—Anxiety—Prednisone—chronic obstructive pulmonary disease	8.52e-05	0.000791	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	8.49e-05	0.000789	CcSEcCtD
Erlotinib—Oedema—Prednisone—chronic obstructive pulmonary disease	8.2e-05	0.000761	CcSEcCtD
Erlotinib—Infection—Prednisone—chronic obstructive pulmonary disease	8.14e-05	0.000756	CcSEcCtD
Erlotinib—Shock—Prednisone—chronic obstructive pulmonary disease	8.07e-05	0.000749	CcSEcCtD
Erlotinib—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	8.04e-05	0.000747	CcSEcCtD
Erlotinib—Skin disorder—Prednisone—chronic obstructive pulmonary disease	7.96e-05	0.000739	CcSEcCtD
Erlotinib—Anorexia—Prednisone—chronic obstructive pulmonary disease	7.81e-05	0.000726	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	7.47e-05	0.000694	CcSEcCtD
Erlotinib—Dizziness—Prednisolone—chronic obstructive pulmonary disease	7.46e-05	0.000693	CcSEcCtD
Erlotinib—Insomnia—Prednisone—chronic obstructive pulmonary disease	7.41e-05	0.000688	CcSEcCtD
Erlotinib—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	7.22e-05	0.00067	CcSEcCtD
Erlotinib—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	7.13e-05	0.000662	CcSEcCtD
Erlotinib—Rash—Prednisolone—chronic obstructive pulmonary disease	7.11e-05	0.00066	CcSEcCtD
Erlotinib—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	7.11e-05	0.00066	CcSEcCtD
Erlotinib—Fatigue—Prednisone—chronic obstructive pulmonary disease	7.07e-05	0.000656	CcSEcCtD
Erlotinib—Headache—Prednisolone—chronic obstructive pulmonary disease	7.07e-05	0.000656	CcSEcCtD
Erlotinib—Constipation—Prednisone—chronic obstructive pulmonary disease	7.01e-05	0.000651	CcSEcCtD
Erlotinib—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	6.7e-05	0.000622	CcSEcCtD
Erlotinib—Nausea—Prednisolone—chronic obstructive pulmonary disease	6.7e-05	0.000622	CcSEcCtD
Erlotinib—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	6.48e-05	0.000602	CcSEcCtD
Erlotinib—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	6.48e-05	0.000602	CcSEcCtD
Erlotinib—Asthenia—Prednisone—chronic obstructive pulmonary disease	5.88e-05	0.000546	CcSEcCtD
Erlotinib—Pruritus—Prednisone—chronic obstructive pulmonary disease	5.8e-05	0.000539	CcSEcCtD
Erlotinib—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	5.61e-05	0.000521	CcSEcCtD
Erlotinib—Dizziness—Prednisone—chronic obstructive pulmonary disease	5.42e-05	0.000503	CcSEcCtD
Erlotinib—Vomiting—Prednisone—chronic obstructive pulmonary disease	5.21e-05	0.000484	CcSEcCtD
Erlotinib—Rash—Prednisone—chronic obstructive pulmonary disease	5.17e-05	0.00048	CcSEcCtD
Erlotinib—Dermatitis—Prednisone—chronic obstructive pulmonary disease	5.16e-05	0.00048	CcSEcCtD
Erlotinib—Headache—Prednisone—chronic obstructive pulmonary disease	5.14e-05	0.000477	CcSEcCtD
Erlotinib—Nausea—Prednisone—chronic obstructive pulmonary disease	4.87e-05	0.000452	CcSEcCtD
Erlotinib—CYP1B1—Metabolism—GCLC—chronic obstructive pulmonary disease	1.29e-05	0.000174	CbGpPWpGaD
Erlotinib—EGFR—Immune System—KL—chronic obstructive pulmonary disease	1.28e-05	0.000174	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.27e-05	0.000173	CbGpPWpGaD
Erlotinib—EGFR—Disease—HDAC2—chronic obstructive pulmonary disease	1.27e-05	0.000173	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.27e-05	0.000172	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—VEGFA—chronic obstructive pulmonary disease	1.26e-05	0.000171	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.26e-05	0.000171	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—CTGF—chronic obstructive pulmonary disease	1.26e-05	0.000171	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—IL6—chronic obstructive pulmonary disease	1.26e-05	0.00017	CbGpPWpGaD
Erlotinib—JAK3—Immune System—IL1B—chronic obstructive pulmonary disease	1.25e-05	0.00017	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.25e-05	0.00017	CbGpPWpGaD
Erlotinib—ALB—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.24e-05	0.000169	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	1.22e-05	0.000165	CbGpPWpGaD
Erlotinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	1.21e-05	0.000165	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CD8A—chronic obstructive pulmonary disease	1.21e-05	0.000164	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.21e-05	0.000163	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.2e-05	0.000163	CbGpPWpGaD
Erlotinib—MKNK1—Disease—TGFB1—chronic obstructive pulmonary disease	1.19e-05	0.000162	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.18e-05	0.000161	CbGpPWpGaD
Erlotinib—EGFR—Disease—KL—chronic obstructive pulmonary disease	1.18e-05	0.00016	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—MMP9—chronic obstructive pulmonary disease	1.18e-05	0.000159	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—CTGF—chronic obstructive pulmonary disease	1.17e-05	0.000159	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GC—chronic obstructive pulmonary disease	1.17e-05	0.000159	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—GCLC—chronic obstructive pulmonary disease	1.17e-05	0.000159	CbGpPWpGaD
Erlotinib—MKNK1—Disease—EGFR—chronic obstructive pulmonary disease	1.17e-05	0.000158	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.16e-05	0.000157	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.16e-05	0.000157	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	1.16e-05	0.000157	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.14e-05	0.000154	CbGpPWpGaD
Erlotinib—ABL1—Immune System—ERBB3—chronic obstructive pulmonary disease	1.13e-05	0.000152	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	1.12e-05	0.000152	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.12e-05	0.000152	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.11e-05	0.000151	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GC—chronic obstructive pulmonary disease	1.11e-05	0.00015	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.09e-05	0.000148	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.08e-05	0.000147	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—CTGF—chronic obstructive pulmonary disease	1.07e-05	0.000145	CbGpPWpGaD
Erlotinib—ALB—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	1.07e-05	0.000145	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—VEGFA—chronic obstructive pulmonary disease	1.06e-05	0.000143	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.05e-05	0.000142	CbGpPWpGaD
Erlotinib—ABCG2—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	1.04e-05	0.000141	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.04e-05	0.00014	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—VEGFA—chronic obstructive pulmonary disease	1.04e-05	0.00014	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.04e-05	0.00014	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CD8A—chronic obstructive pulmonary disease	1.03e-05	0.00014	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CRP—chronic obstructive pulmonary disease	1.03e-05	0.000139	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.03e-05	0.000139	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—IL6—chronic obstructive pulmonary disease	1.02e-05	0.000139	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.01e-05	0.000137	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.01e-05	0.000137	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—MMP9—chronic obstructive pulmonary disease	1.01e-05	0.000136	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	9.98e-06	0.000135	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	9.97e-06	0.000135	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	9.91e-06	0.000134	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—VEGFA—chronic obstructive pulmonary disease	9.9e-06	0.000134	CbGpPWpGaD
Erlotinib—ABL1—Immune System—TLR4—chronic obstructive pulmonary disease	9.86e-06	0.000134	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—CYP1A2—chronic obstructive pulmonary disease	9.85e-06	0.000133	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—MMP1—chronic obstructive pulmonary disease	9.77e-06	0.000132	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	9.74e-06	0.000132	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—TGFB1—chronic obstructive pulmonary disease	9.69e-06	0.000131	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—GSTP1—chronic obstructive pulmonary disease	9.68e-06	0.000131	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—IL6—chronic obstructive pulmonary disease	9.67e-06	0.000131	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	9.62e-06	0.00013	CbGpPWpGaD
Erlotinib—EGFR—Immune System—ERBB3—chronic obstructive pulmonary disease	9.61e-06	0.00013	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—PLAU—chronic obstructive pulmonary disease	9.59e-06	0.00013	CbGpPWpGaD
Erlotinib—JAK3—Immune System—EGFR—chronic obstructive pulmonary disease	9.55e-06	0.000129	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—HMOX1—chronic obstructive pulmonary disease	9.55e-06	0.000129	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	9.53e-06	0.000129	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—TGFB1—chronic obstructive pulmonary disease	9.51e-06	0.000129	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—EGFR—chronic obstructive pulmonary disease	9.51e-06	0.000129	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GC—chronic obstructive pulmonary disease	9.36e-06	0.000127	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	9.35e-06	0.000127	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	9.1e-06	0.000123	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—TGFB1—chronic obstructive pulmonary disease	9.08e-06	0.000123	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—TNF—chronic obstructive pulmonary disease	9.05e-06	0.000123	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—GSTP1—chronic obstructive pulmonary disease	9.03e-06	0.000122	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—VEGFA—chronic obstructive pulmonary disease	9.03e-06	0.000122	CbGpPWpGaD
Erlotinib—MKNK1—Disease—IL6—chronic obstructive pulmonary disease	8.99e-06	0.000122	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	8.94e-06	0.000121	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	8.92e-06	0.000121	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—HMOX1—chronic obstructive pulmonary disease	8.9e-06	0.000121	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—GSTM1—chronic obstructive pulmonary disease	8.89e-06	0.000121	CbGpPWpGaD
Erlotinib—EGFR—Disease—ERBB3—chronic obstructive pulmonary disease	8.88e-06	0.00012	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—NOS2—chronic obstructive pulmonary disease	8.81e-06	0.000119	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CRP—chronic obstructive pulmonary disease	8.79e-06	0.000119	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	8.77e-06	0.000119	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—IL6—chronic obstructive pulmonary disease	8.75e-06	0.000119	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	8.7e-06	0.000118	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—GSTT1—chronic obstructive pulmonary disease	8.49e-06	0.000115	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	8.45e-06	0.000114	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	8.43e-06	0.000114	CbGpPWpGaD
Erlotinib—EGFR—Immune System—TLR4—chronic obstructive pulmonary disease	8.43e-06	0.000114	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—EGFR—chronic obstructive pulmonary disease	8.4e-06	0.000114	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—GCLC—chronic obstructive pulmonary disease	8.39e-06	0.000114	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	8.35e-06	0.000113	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	8.35e-06	0.000113	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—GSTM1—chronic obstructive pulmonary disease	8.3e-06	0.000112	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—KL—chronic obstructive pulmonary disease	8.29e-06	0.000112	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—TGFB1—chronic obstructive pulmonary disease	8.28e-06	0.000112	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—GSTP1—chronic obstructive pulmonary disease	8.21e-06	0.000111	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	8.19e-06	0.000111	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	8.13e-06	0.00011	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—HMOX1—chronic obstructive pulmonary disease	8.1e-06	0.00011	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	8.03e-06	0.000109	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—GSTT1—chronic obstructive pulmonary disease	8.02e-06	0.000109	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—GCLC—chronic obstructive pulmonary disease	7.93e-06	0.000107	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	7.86e-06	0.000107	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—TP53—chronic obstructive pulmonary disease	7.83e-06	0.000106	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	7.76e-06	0.000105	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—TNF—chronic obstructive pulmonary disease	7.74e-06	0.000105	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CTGF—chronic obstructive pulmonary disease	7.66e-06	0.000104	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	7.65e-06	0.000104	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	7.64e-06	0.000104	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—GSTM1—chronic obstructive pulmonary disease	7.55e-06	0.000102	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	7.43e-06	0.000101	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	7.42e-06	0.0001	CbGpPWpGaD
Erlotinib—EGFR—Disease—NOS2—chronic obstructive pulmonary disease	7.4e-06	0.0001	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	7.39e-06	0.0001	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	7.36e-06	9.97e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GSTT1—chronic obstructive pulmonary disease	7.35e-06	9.96e-05	CbGpPWpGaD
Erlotinib—JAK3—Immune System—IL6—chronic obstructive pulmonary disease	7.34e-06	9.95e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GSTT1—chronic obstructive pulmonary disease	7.31e-06	9.91e-05	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—IL6—chronic obstructive pulmonary disease	7.31e-06	9.9e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GCLC—chronic obstructive pulmonary disease	7.27e-06	9.85e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CTGF—chronic obstructive pulmonary disease	7.23e-06	9.8e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GCLC—chronic obstructive pulmonary disease	7.23e-06	9.79e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	7.22e-06	9.79e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	7.15e-06	9.69e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—NOS3—chronic obstructive pulmonary disease	7.08e-06	9.59e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CYP1A2—chronic obstructive pulmonary disease	7.06e-06	9.56e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	6.93e-06	9.39e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	6.89e-06	9.33e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	6.88e-06	9.32e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	6.86e-06	9.3e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	6.84e-06	9.26e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	6.78e-06	9.18e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	6.72e-06	9.1e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.67e-06	9.03e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CTGF—chronic obstructive pulmonary disease	6.63e-06	8.99e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CTGF—chronic obstructive pulmonary disease	6.59e-06	8.93e-05	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—IL6—chronic obstructive pulmonary disease	6.45e-06	8.74e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL1B—chronic obstructive pulmonary disease	6.42e-06	8.69e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GSTT1—chronic obstructive pulmonary disease	6.41e-06	8.68e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GCLC—chronic obstructive pulmonary disease	6.33e-06	8.58e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	6.3e-06	8.53e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	6.29e-06	8.53e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	6.26e-06	8.48e-05	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—IL6—chronic obstructive pulmonary disease	6.24e-06	8.46e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—SERPINE1—chronic obstructive pulmonary disease	6.23e-06	8.44e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	6.23e-06	8.44e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	6.22e-06	8.42e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	6.18e-06	8.37e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.11e-06	8.28e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.08e-06	8.23e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	6.04e-06	8.18e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	5.98e-06	8.11e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	5.97e-06	8.08e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—NOS3—chronic obstructive pulmonary disease	5.95e-06	8.06e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.88e-06	7.97e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.8e-06	7.86e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CTGF—chronic obstructive pulmonary disease	5.78e-06	7.83e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—ALB—chronic obstructive pulmonary disease	5.73e-06	7.77e-05	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	5.61e-06	7.61e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	5.59e-06	7.58e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—LEP—chronic obstructive pulmonary disease	5.56e-06	7.54e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.56e-06	7.53e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—IL6—chronic obstructive pulmonary disease	5.51e-06	7.47e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL1B—chronic obstructive pulmonary disease	5.48e-06	7.43e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.48e-06	7.43e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—NOS3—chronic obstructive pulmonary disease	5.48e-06	7.43e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	5.45e-06	7.38e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.41e-06	7.33e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—ALB—chronic obstructive pulmonary disease	5.35e-06	7.24e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	5.32e-06	7.21e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TP53—chronic obstructive pulmonary disease	5.19e-06	7.02e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	5.13e-06	6.96e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.13e-06	6.94e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GSTT1—chronic obstructive pulmonary disease	5.11e-06	6.93e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—NOS3—chronic obstructive pulmonary disease	5.11e-06	6.93e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.11e-06	6.92e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—VEGFA—chronic obstructive pulmonary disease	5.1e-06	6.91e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.1e-06	6.91e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.07e-06	6.87e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GCLC—chronic obstructive pulmonary disease	5.06e-06	6.85e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	5.03e-06	6.82e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.03e-06	6.81e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	5.02e-06	6.8e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—HMOX1—chronic obstructive pulmonary disease	5e-06	6.77e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—EGFR—chronic obstructive pulmonary disease	4.89e-06	6.62e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—ALB—chronic obstructive pulmonary disease	4.86e-06	6.59e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.75e-06	6.43e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	4.71e-06	6.39e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.68e-06	6.35e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TGFB1—chronic obstructive pulmonary disease	4.68e-06	6.34e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.66e-06	6.31e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—NOS3—chronic obstructive pulmonary disease	4.65e-06	6.3e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CTGF—chronic obstructive pulmonary disease	4.61e-06	6.25e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.44e-06	6.02e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.44e-06	6.02e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.41e-06	5.98e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.38e-06	5.93e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	4.36e-06	5.91e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.23e-06	5.73e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.18e-06	5.67e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	4.17e-06	5.65e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.13e-06	5.59e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.08e-06	5.53e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	3.95e-06	5.35e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—TGFB1—chronic obstructive pulmonary disease	3.93e-06	5.33e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	3.9e-06	5.29e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.87e-06	5.24e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.87e-06	5.24e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TP53—chronic obstructive pulmonary disease	3.85e-06	5.22e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.85e-06	5.21e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL6—chronic obstructive pulmonary disease	3.76e-06	5.09e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.7e-06	5.01e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.65e-06	4.94e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	3.56e-06	4.82e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.54e-06	4.8e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.51e-06	4.76e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.5e-06	4.74e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—ALB—chronic obstructive pulmonary disease	3.48e-06	4.72e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.34e-06	4.53e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—NOS3—chronic obstructive pulmonary disease	3.33e-06	4.52e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ALB—chronic obstructive pulmonary disease	3.29e-06	4.46e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	3.28e-06	4.44e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.26e-06	4.41e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL6—chronic obstructive pulmonary disease	3.21e-06	4.35e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—NOS3—chronic obstructive pulmonary disease	3.15e-06	4.27e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.09e-06	4.18e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ALB—chronic obstructive pulmonary disease	3.02e-06	4.09e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3e-06	4.07e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—IL6—chronic obstructive pulmonary disease	2.96e-06	4.02e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—NOS3—chronic obstructive pulmonary disease	2.89e-06	3.91e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—NOS3—chronic obstructive pulmonary disease	2.87e-06	3.89e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.76e-06	3.73e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.74e-06	3.71e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.7e-06	3.66e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ALB—chronic obstructive pulmonary disease	2.63e-06	3.56e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—NOS3—chronic obstructive pulmonary disease	2.52e-06	3.41e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.51e-06	3.41e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	2.48e-06	3.36e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.38e-06	3.23e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	2.37e-06	3.21e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.27e-06	3.07e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ALB—chronic obstructive pulmonary disease	2.1e-06	2.84e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.08e-06	2.81e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—NOS3—chronic obstructive pulmonary disease	2.01e-06	2.72e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	1.62e-06	2.19e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	1.55e-06	2.1e-05	CbGpPWpGaD
